These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 10493963)

  • 21. [New therapeutic approaches in non-small-cell lung carcinoma (NSCLC), stages IV].
    Mavroudis D
    Rev Pneumol Clin; 2001 Nov; 57(5 Pt 2):S42-5. PubMed ID: 11924243
    [No Abstract]   [Full Text] [Related]  

  • 22. Sensitivity to topoisomerase I inhibitors and cisplatin is associated with epidermal growth factor receptor expression in human cervical squamous carcinoma ME180 sublines.
    Ling YH; Donato NJ; Perez-Soler R
    Cancer Chemother Pharmacol; 2001 Jun; 47(6):473-80. PubMed ID: 11459199
    [TBL] [Abstract][Full Text] [Related]  

  • 23. ErbB3 expression predicts sensitivity to elisidepsin treatment: in vitro synergism with cisplatin, paclitaxel and gemcitabine in lung, breast and colon cancer cell lines.
    Teixidó C; Arguelaguet E; Pons B; Aracil M; Jimeno J; Somoza R; Marés R; Ramón Y Cajal S; Hernández-Losa J
    Int J Oncol; 2012 Jul; 41(1):317-24. PubMed ID: 22485250
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Bone marrow and tumor cell colony-forming units and human tumor xenograft efficacy of noncamptothecin and camptothecin topoisomerase I inhibitors.
    Kurtzberg LS; Battle T; Rouleau C; Bagley RG; Agata N; Yao M; Schmid S; Roth S; Crawford J; Krumbholz R; Ewesuedo R; Yu XJ; Wang F; Lavoie EJ; Teicher BA
    Mol Cancer Ther; 2008 Oct; 7(10):3212-22. PubMed ID: 18852125
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Challenging the platinum combinations in the chemotherapy of NSCLC.
    Douillard JY; Eckardt J; Scagliotti GV
    Lung Cancer; 2002 Dec; 38 Suppl 4():21-8. PubMed ID: 12480191
    [TBL] [Abstract][Full Text] [Related]  

  • 26. BCRP/ABCG2 levels account for the resistance to topoisomerase I inhibitors and reversal effects by gefitinib in non-small cell lung cancer.
    Nagashima S; Soda H; Oka M; Kitazaki T; Shiozawa K; Nakamura Y; Takemura M; Yabuuchi H; Fukuda M; Tsukamoto K; Kohno S
    Cancer Chemother Pharmacol; 2006 Nov; 58(5):594-600. PubMed ID: 16520985
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prediction of cell kill kinetics of anticancer agents using the collagen gel droplet embedded-culture drug sensitivity test.
    Mori T; Ohnishi M; Komiyama M; Tsutsui A; Yabushita H; Okada H
    Oncol Rep; 2002; 9(2):301-5. PubMed ID: 11836596
    [TBL] [Abstract][Full Text] [Related]  

  • 28. New anticancer agents in clinical development.
    Eckardt J; Eckhardt G; Villalona-Calero M; Drengler R; Von Hoff D
    Oncology (Williston Park); 1995 Nov; 9(11):1191-9. PubMed ID: 8703688
    [TBL] [Abstract][Full Text] [Related]  

  • 29. New chemotherapeutic agents for non-small cell lung cancer.
    Miller VA; Rigas JR; Grant SC; Pisters KM; Kris MG
    Chest; 1995 Jun; 107(6 Suppl):306S-311S. PubMed ID: 7781411
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Second-line chemotherapy for recurrent non-small cell lung cancer: do new agents make a difference?
    Ferrigno D; Buccheri G
    Lung Cancer; 2000 Aug; 29(2):91-104. PubMed ID: 10963840
    [TBL] [Abstract][Full Text] [Related]  

  • 31. In vitro study of CI-994, a histone deacetylase inhibitor, in non-small cell lung cancer cell lines.
    Loprevite M; Tiseo M; Grossi F; Scolaro T; Semino C; Pandolfi A; Favoni R; Ardizzoni A
    Oncol Res; 2005; 15(1):39-48. PubMed ID: 15839304
    [TBL] [Abstract][Full Text] [Related]  

  • 32. E2F inhibition synergizes with paclitaxel in lung cancer cell lines.
    Kurtyka CA; Chen L; Cress WD
    PLoS One; 2014; 9(5):e96357. PubMed ID: 24831239
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor.
    Ciardiello F; Caputo R; Bianco R; Damiano V; Pomatico G; De Placido S; Bianco AR; Tortora G
    Clin Cancer Res; 2000 May; 6(5):2053-63. PubMed ID: 10815932
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Rationale for non-platinum chemotherapy in advanced NSCLC.
    Murren JR
    Oncology (Williston Park); 2001 Jul; 15(7 Suppl 8):29-34. PubMed ID: 11497229
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Current perspectives of new agents in lung cancer].
    Fukuoka M
    Nihon Rinsho; 2000 May; 58(5):1103-10. PubMed ID: 10824557
    [TBL] [Abstract][Full Text] [Related]  

  • 36. mRNA expression of RRM1, ERCC1 and ERCC2 is not associated with chemosensitivity to cisplatin, carboplatin and gemcitabine in human lung cancer cell lines.
    Shimizu J; Horio Y; Osada H; Hida T; Hasegawa Y; Shimokata K; Takahashi T; Sekido Y; Yatabe Y
    Respirology; 2008 Jun; 13(4):510-7. PubMed ID: 18494946
    [TBL] [Abstract][Full Text] [Related]  

  • 37. In vitro sensitivity of human endometrial cancer cell lines to paclitaxel or irinotecan (CPT-11) in combination with other aniticancer drugs.
    Hiramatsu HP; Kikuchi Y; Seto H; Nagata I
    Anticancer Drugs; 2000 Aug; 11(7):573-8. PubMed ID: 11036961
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Establishment of patient-derived non-small cell lung cancer xenografts as models for the identification of predictive biomarkers.
    Fichtner I; Rolff J; Soong R; Hoffmann J; Hammer S; Sommer A; Becker M; Merk J
    Clin Cancer Res; 2008 Oct; 14(20):6456-68. PubMed ID: 18927285
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparative benefits of Nab-paclitaxel over gemcitabine or polysorbate-based docetaxel in experimental pancreatic cancer.
    Awasthi N; Zhang C; Schwarz AM; Hinz S; Wang C; Williams NS; Schwarz MA; Schwarz RE
    Carcinogenesis; 2013 Oct; 34(10):2361-9. PubMed ID: 23803690
    [TBL] [Abstract][Full Text] [Related]  

  • 40. New chemotherapeutic agents prolong survival and improve quality of life in non-small cell lung cancer: a review of the literature and future directions.
    Bunn PA; Kelly K
    Clin Cancer Res; 1998 May; 4(5):1087-100. PubMed ID: 9607565
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.